Clinical Trials Logo

Filter by:
NCT ID: NCT03197272 Recruiting - Myopia Clinical Trials

Advanced Cross Linking for Low-grade Myopia

PiXLO2
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

To evaluate the improvement in myopic refractive error and the corneal endothelial safety with a corneal crosslinking treatment regimen for mild myopia. The treatment involves a 4-mm central treatment zone in high oxygen environment without corneal epithelial debridement.

NCT ID: NCT03196713 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Early Intervention, Supervision, Quality and Outcome in ASD

Start date: April 1, 2013
Phase: N/A
Study type: Interventional

The objective of this study is to examine the significance of knowledge of autism spectrum disorder (ASD), and early intensive behavioral intervention, as well as trust in EIBI, adequate assessment of EIBI quality, and EIBI supervision on EIBI intervention outcome in ASD.

NCT ID: NCT03196297 Not yet recruiting - Haemophilia A Clinical Trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

explorerâ„¢5
Start date: August 15, 2017
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

NCT ID: NCT03196284 Not yet recruiting - Clinical trials for Congenital Bleeding Disorder

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

explorerâ„¢4
Start date: August 15, 2017
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.

NCT ID: NCT03193866 Recruiting - Clinical trials for Relapsing-remitting Multiple Sclerosis

COMparison Between All immunoTherapies for Multiple Sclerosis.

COMBAT-MS
Start date: February 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).

NCT ID: NCT03193671 Completed - Clinical trials for Ovarian Cancer, Biomarkers, Diagnosis, Algorithms

Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis

Start date: September 1, 2013
Phase: N/A
Study type: Observational [Patient Registry]

This study evaluates the biomarkers CA125 and HE4 and the algorithms RMI and ROMA on a normal population in the western region of Sweden. The aim is to improve diagnosis of ovarian cancer. If we observe a clear improvement in the early diagnosis of EOC, we aim to implement the best strategy for all patients with suspected pelvic tumor mass in the western region of Sweden.

NCT ID: NCT03192969 Not yet recruiting - Clinical trials for Giant Cell Arteritis

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Start date: July 15, 2017
Phase: Phase 3
Study type: Interventional

To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.

NCT ID: NCT03192956 Recruiting - Clinical trials for Decompression Sickness

Markers of Central Nervous System Injury in Decompression Sickness

DCS NEURO
Start date: May 1, 2017
Phase: N/A
Study type: Observational

Research hypothesis - There is a correlation between the quantity of fluid markers of CNS injury in blood and DCS. - There is a correlation between quantity and kind of fluid markers of CNS injury in blood and both diving profile and severity of DCS. - There is a correlation between the quantity of inflammatory markers in blood an DCS. Objectives: - Assess whether individuals suffering decompression sickness exhibit fluid markers of central nervous system injury. - Evaluate the correlation between quantity and kind of fluid marker of CNS injury and clinical signs of neurological impairment. - Evaluate the correlation between quantity and kind of fluid marker of CNS injury and clinical outcome after 3-6 months. - Assess whether individuals suffering decompression sickness exhibit inflammatory markers in blood.

NCT ID: NCT03192930 Recruiting - Hyperbaric Exposure Clinical Trials

Inflammatory and Cerebrospinal Biochemical Markers in Blood During Prolonged Hyperbaric Exposure

Mättnad 2017
Start date: March 17, 2017
Phase: N/A
Study type: Observational

Research hypothesis - Prolonged hyperbaric exposure will affect the central nervous system - Prolonged hyperbaric exposure will induce inflammatory changes - Prolonged hyperbaric exposure will affect fluid regulation in the body Objectives: - To investigate the presence of cerebrospinal biochemical markers in blood during prolonged hyperbaric exposure - To investigate changes in the quantity of cerebrospinal biochemical markers in blood during decompression after prolonged hyperbaric exposure - To investigate the presence of inflammatory markers in blood during prolonged hyperbaric exposure - To investigate changes in the quantity of inflammatory markers in blood during decompression after prolonged hyperbaric exposure - To investigate if prolonged hyperbaric exposure alters fluid balance in the body

NCT ID: NCT03190252 Recruiting - Inflammation Clinical Trials

Inflammatory and Cerebrospinal Biochemical Markers in Blood After Trimix Diving

TriMix17-18
Start date: June 12, 2017
Phase: N/A
Study type: Observational

Research hypothesis - Diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas will affect the central nervous system. - Diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas will induce inflammatory changes. Objectives: - To investigate the presence of cerebrospinal biochemical markers in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas. - To investigate the presence of inflammatory markers in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas. - To investigate the presence of venous gas emboli (VGE) in blood after diving to depths up to 90msw with an oxygen partial pressure of 130kPa in the breathing gas.